Finally, association analysis performed on more than 1500 melanoma samples showed that ARID2 mutation correlates with higher immune response markers such as TMB (tumor mutational burden), PDl-1 expression, and dMMR/MSI-H compared to ARID2-WT (Akinjiyan et al. 2024). This evidence concerns the gene ARID2 and neoplasm.